Viral vector

Xtalks Announces its Life Science Webinar Calendar for February 2024

Retrieved on: 
Thursday, February 1, 2024
Viral vector, Biomarker, IRT, Robert Williams (robot fatality), Food, Temperature, Skin, Spray drying, Use, Monoclonal antibody, Drug discovery, Metabolism, Automation, Superior, Series, Pharmaceutical industry, Molality, Medical imaging

TORONTO, Feb. 1, 2024 /PRNewswire-PRWeb/ -- Stay on top of current hot topics through free webinars presented by leading experts in the pharma, biotech, medical device and food industries. Access to all webinars is free, so be sure to register today to save your place! Participate in the discussion and stay relevant in your field!

Key Points: 
  • Upcoming free, educational webinars from Xtalks will feature topics on biomarkers, clinical trials, drug discovery & development, food, fundamental research, laboratory technology, patient recruitment & retention, pharmaceutical, pharma manufacturing & supply chain and pharmaceutical regulation
    TORONTO, Feb. 1, 2024 /PRNewswire-PRWeb/ -- Stay on top of current hot topics through free webinars presented by leading experts in the pharma, biotech, medical device and food industries.
  • Access to all webinars is free, so be sure to register today to save your place!
  • Participate in the discussion and stay relevant in your field!
  • Visit http://www.xtalks.com to see our upcoming webinars:
    February 15 - Case Study: EEG Digital Biomarkers in Neuropsychiatric Clinical Studies
    February 15 - Streamlining IRT in Clinical Trials: Simplify, Optimise, Succeed
    February 22 - Endpoint Protection in Rare Disease Trials: Safeguarding Data Integrity for Reliable Outcomes
    February 22 - Responsibly Advancing the Use of AI in Clinical Trials: Current Landscape, Common Misconceptions and Future Opportunities
    February 5 - Unlocking Superior R&D Results: Mastering the FSP Model
    February 14 - Explore the Missing Links of Beauty, Skin, Hair and Joint Wellness
    February 21 - Metabolic Health Trends: The Future of Balanced Wellness
    February 8 - Optimizing Monoclonal Antibody Production: Temperature and Osmolality's Impact
    February 12 and 13 - Electrostatic Spray Drying: A Drying Alternative for Thermosensitive Products (2-Part Series)
    February 27 - Upstream Bioprocessing: DoE Optimization for CHO Cell Cultures
    February 5 - Trial Recruitment Optimization: 5 Reasons Why the Right People Aren't Joining Your Trials
    February 7 - Viral Vector Manufacturing Success Stories: Onboarding to GMP Production
    February 20 - Warehouse Automation Within the Pharmaceutical Industry: Logistics from Dock to Dock

SmartCella strengthens team by recruiting Dr. Nina Bauer as Chief Business Officer

Retrieved on: 
Wednesday, January 3, 2024
RNA, Master of Business Administration, Master, Karolinska University Hospital, Commercial, AstraZeneca, Research, Viral vector, FDA, Acquisition, Cell, Stony Brook University, Business administration, MBA, Sigma-Aldrich, Doctor of Philosophy, Gene, GMP, University of Oldenburg, University, Business development, Neoplasm, Cancer, Growth, Patient, Publication, Head, Therapy, Management

STOCKHOLM, Jan. 3, 2024 /PRNewswire/ -- SmartCella Holding AB today announces that Dr. Nina Bauer, MBA, has been appointed Chief Business Officer and Head of Smartwise.

Key Points: 
  • STOCKHOLM, Jan. 3, 2024 /PRNewswire/ -- SmartCella Holding AB today announces that Dr. Nina Bauer, MBA, has been appointed Chief Business Officer and Head of Smartwise.
  • She will be a member of the SmartCella Exceutive Management Team, and based in Boston (MA, USA).
  • With the strategic recruitment of Nina Bauer, SmartCella is accelerating its expansion plans and gearing up to enter the US market.
  • Nina Bauer says: "SmartCella was like a hidden gem to me, innovative and entrepreneurial in a very hot and fast developing research area.

NIIMBL Launches Viral Vector Program to Help Improve Patient Access to AAV Gene Therapy

Retrieved on: 
Tuesday, October 10, 2023
Vector (mathematics and physics), Hope, Government, Viral vector, University, Doctor of Philosophy, Ecosystem, Workforce, AAV, NIIMBL, Rare, University of Massachusetts Chan Medical School, Viral, Patient, Vaccine

"There are thousands of rare diseases, many of which could be candidates for AAV-based gene therapy.

Key Points: 
  • "There are thousands of rare diseases, many of which could be candidates for AAV-based gene therapy.
  • The initial structure of the Viral Vector Program will include:
    Additionally, a key component of the Viral Vector Program includes a parallel initiative in workforce development for key capabilities in AAV vector manufacturing and analytics.
  • NIIMBL will be hosting a webinar on the Viral Vector program on November 15, 2023.
  • To register for the webinar and to learn more about NIIMBL and the Viral Vector program, visit NIIMBL.org/ViralVector .

AGC Biologics Partners with Asahi Kasei Pharma Corporation on Clinical Antibody Project

Retrieved on: 
Tuesday, August 15, 2023
Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, Messenger RNA, Plasmid, Viral vector, Perfusion, Cell therapy, AGC, History, Messenger, Food and Drug Administration, CDMO, CGMP, FDA, Food, Fine chemical

AGC Biologics , a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced a new agreement with Asahi Kasei Pharma Corporation to produce clinical drug substance for antibody-based therapies at AGC Biologics’ Seattle manufacturing site.

Key Points: 
  • AGC Biologics , a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced a new agreement with Asahi Kasei Pharma Corporation to produce clinical drug substance for antibody-based therapies at AGC Biologics’ Seattle manufacturing site.
  • Under the agreement, AGC Biologics will leverage its monoclonal antibody development and manufacturing experience to perform process transfer, process optimization, and clinical manufacturing of the Asahi Kasei Pharma drug substance.
  • “We look forward to partnering with Asahi Kasei Pharma to help achieve their goals with this important project.”
    AGC Biologics runs multiple mammalian cGMP manufacturing lines at various scales at its Seattle facility.
  • To learn more about AGC Biologics’ biologics manufacturing site in Seattle, visit www.agcbio.com/facilities/seattle .

NIIMBL Announces a Request for Information (RFI) for Potential Participation in a Next-Generation Sequencing Method Development Study for Characterization of AAV-based Gene Therapy Vectors

Retrieved on: 
Thursday, August 10, 2023
Viral vector, NGS, Request for information, RFI, VV, AAV, NIIMBL, Massive parallel sequencing, RFA, Vaccine, Risk management

The objectives for this study are method development, sharing of best practices, and the establishment of a common protocol among the project teams.

Key Points: 
  • The objectives for this study are method development, sharing of best practices, and the establishment of a common protocol among the project teams.
  • "As NIIMBL prepares for the launch of the Viral Vector (VV) Program, this study will be significant in developing a robust and reproducible NGS-based AAV characterization method for use within the Program.
  • NIIMBL expects to release a Request for Application (RFA) based on capabilities assessments from the RFI2023.1 responses.
  • For key dates, important information, and how to apply, go to the NGS Interlaboratory Study RFI page .

AGC Biologics Completes Expansion at Milan Cell and Gene Therapy Development and Manufacturing Site

Retrieved on: 
Wednesday, August 9, 2023
Biotechnology, Pharmaceutical, Health, Messenger RNA, GMP, DNA, Plasmid, Gene, Center for Cell and Gene Therapy, Viral vector, Gene-centered view of evolution, AGC, Messenger, CDMO, CGMP, Cell, Heidelberg, Vaccine

AGC Biologics , a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced the company completed the expansion of its manufacturing space at its Milan Cell & Gene Center of Excellence production site.

Key Points: 
  • AGC Biologics , a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced the company completed the expansion of its manufacturing space at its Milan Cell & Gene Center of Excellence production site.
  • “This is another important milestone for our site and for the AGC Biologics global Cell and Gene network as we prepare to serve more developers,” said Luca Alberici, General Manager, AGC Biologics Milan.
  • AGC Biologics operates two cell and gene facilities within its global network, one in Milan and one in Longmont, Col, USA.
  • At each site AGC Biologics offers end-to-end global viral vector and cell therapy development, manufacturing, and quality/regulatory services, using the latest technology platforms and scientific methods.

Cell Easy Appoints CDMO Expert Dr. Sebastien Ribault as Independent Board Director, to Accelerate Its Rapid Growth

Retrieved on: 
Thursday, May 11, 2023
Stem Cells, Biotechnology, Manufacturing, Health, Pharmaceutical, Oncology, Medical Devices, Research, Other Manufacturing, Science, Clinical Trials, GMP, Good manufacturing practice, Oxford Biomedica, Viral vector, Chief commercial officer, Stem cell, NK, Doctor of Philosophy, Microsoft Exchange Server, SAS, CDMO, Growth, Entrepreneurship, Fine chemical, Vaccine

Cell-Easy SAS (“Cell-Easy”), a rapidly growing Contract Development and Manufacturing Organization (“CDMO”) that specializes in cell therapy, has appointed Dr. Sebastien Ribault, PhD, to its board of directors, to further accelerate its growth.

Key Points: 
  • Cell-Easy SAS (“Cell-Easy”), a rapidly growing Contract Development and Manufacturing Organization (“CDMO”) that specializes in cell therapy, has appointed Dr. Sebastien Ribault, PhD, to its board of directors, to further accelerate its growth.
  • Since 2020, the company keeps expanding into genetically modified cells such as CAR-T and CAR-NK, while also broadening its service offerings of development and analytical services.
  • To further accelerate its expansion plans and drive leadership in the immune cell therapy market, Cell-Easy is pleased to announce the appointment of Sebastien Ribault, PhD, to its board of directors.
  • Sebastien brings nearly three decades of executive leadership in the CDMO and biotechnology industries, including successful experience in end-to-end CDMO expansion.

AGC Biologics Supports Commercial Production of Provention Bio’s New Type 1 Diabetes (T1D) Therapy, TZIELD™

Retrieved on: 
Tuesday, January 24, 2023
Biotechnology, Diabetes, Pharmaceutical, Health, CDMO, Food and Drug Administration, Life, Cell therapy, Messenger, Ageing, Perfusion, Patient, AGC, PPQ, Medicine, T1D, Plasmid, Messenger RNA, FDA, Autoimmune disease, CGMP, Viral vector, Fine chemical, Pharmaceutical industry

AGC Biologics , a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced a new commercial manufacturing project at its Seattle protein biologics manufacturing site.

Key Points: 
  • AGC Biologics , a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced a new commercial manufacturing project at its Seattle protein biologics manufacturing site.
  • The AGC Biologics Seattle campus has produced biologics products for 30 years and has a long history of successful inspections by the FDA and commercial production.
  • “Congratulations to Provention Bio on this game-changing achievement for T1D patients,” said Kevin Ingham, General Manager of AGC Biologics’ Seattle site.
  • “We at AGC Biologics are proud to have helped develop this innovative new medicine and to be manufacturing it for commercial distribution.

AGC Biologics Supports Altheia Science’s Gene Therapy Programs

Retrieved on: 
Thursday, July 28, 2022
DNA, Specialization, GLOBE, Industry, Partnership, Contract, LVV, GMP, RNA transfection, Cancer, CDMO, Cell, Cell therapy, AGC, PD-L1, Technology, Autoimmunity, Viral vector, MD, Viral, Patient, Plasmid, Degenerative disease, Doctor of Philosophy, Science, RNA, Vaccine

SEATTLE, MILAN, July 28, 2022 (GLOBE NEWSWIRE) -- AGC Biologics , a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced a new partnership with Altheia Science, a gene therapy company pioneering cell and gene therapy strategies to treat autoimmune diseases and cancer.

Key Points: 
  • SEATTLE, MILAN, July 28, 2022 (GLOBE NEWSWIRE) -- AGC Biologics , a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced a new partnership with Altheia Science, a gene therapy company pioneering cell and gene therapy strategies to treat autoimmune diseases and cancer.
  • The AGC Biologics Milan site has a long-standing expertise in successfully developing stem cell-based gene therapies, from clinical testing up to commercialization, said Paolo Rizzardi, Chief Executive Officer of Altheia Science.
  • We believe this partnership is key in supporting our gene therapy programs and making these innovative therapies available to patients."
  • Altheia Science develops pioneering cell & gene therapy strategies to treat autoimmune diseases and cancer.

Examining the Use of Osmolality within Viral Vector Manufacturing, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Monday, June 13, 2022
Industry, Use, Overalls, Workflow, Efficiency, Viral vector, Food, Molality, Vaccine

TORONTO, June 13, 2022 /PRNewswire-PRWeb/ -- Osmolality, a measure of solute concentration, can have many applications throughout the entirety of the cell and gene therapy process. Low yield, the quality of product and the efficiency of the overall workflow are three current pain points for scientists within viral vector production and manufacturing. Increasing the manufacturing capacity, improving the production yields and the improvement of the supply chain logistics, can make these therapies accessible to larger patient populations, with a focus on a sustainable cost.

Key Points: 
  • In this free webinar, learn about the control of osmolality throughout the viral vector workflow and what this may mean for future process improvement within the field.
  • Low yield, the quality of product and the efficiency of the overall workflow are three current pain points for scientists within viral vector production and manufacturing.
  • In this webinar, the featured speaker will examine the use of osmolality within viral vector manufacturing.
  • For more information, or to register for this event, visit Examining the Use of Osmolality within Viral Vector Manufacturing.